Cargando…

A Method for Biomarker Directed Survival Prediction in Advanced Non-Small-Cell Lung Cancer Patients Treated with Carboplatin-Based Therapy

Platinum-based chemotherapy is a primary treatment of choice for advanced non-small-cell lung cancer (NSCLC). Analytical methods to specifically evaluate biomarkers predictive of therapeutic efficacy have not been developed. Two randomized phase III trials of carboplatin-based chemotherapy in advanc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Wei, Bepler, Gerold
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3859458/ https://www.ncbi.nlm.nih.gov/pubmed/24349760 http://dx.doi.org/10.3390/jpm3030251

Ejemplares similares

Sphingosine kinase-1 predicts overall survival outcomes in non-small cell lung cancer patients treated with carboplatin and navelbine
por: Gachechiladze, Mariam, et al.
Publicado: (2019)

Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients
por: Zhang, Guan-Zhong, et al.
Publicado: (2010)

Assessment of quality of life in patients with advanced non-small cell lung carcinoma treated with a combination of carboplatin and paclitaxel
por: Avelino, Camila Uanne Resende, et al.
Publicado: (2015)

Cisplatin or carboplatin for advanced non-small cell lung cancer: does it really matter?
por: Kesireddy, Meghana, et al.
Publicado: (2021)

Hospitalization and Survival of Medicare Patients Treated With Carboplatin Plus Paclitaxel or Pemetrexed for Metastatic, Nonsquamous, Non–Small Cell Lung Cancer
por: Brooks, Gabriel A., et al.
Publicado: (2018)

Survival Analysis and Clinical Outcomes between Paclitaxel and Carboplatin Versus Carboplatin and Gemcitabine in Patients with Advanced-stage Non-small-cell Lung Cancer: A Single-center Cohort Study
por: Boonsong, Thitaya, et al.
Publicado: (2022)

Amrubicin: potential in combination with cisplatin or carboplatin to treat small-cell lung cancer
por: Ding, Qian, et al.
Publicado: (2013)

Atezolizumab in combination with carboplatin and etoposide for heavily treated small cell lung cancer
por: Kataoka, Nobutaka, et al.
Publicado: (2020)

Analysis of continuous first-line treatment with docetaxel and carboplatin for advanced non-small cell lung cancer
por: AOKI, TAKUYA, et al.
Publicado: (2014)

Phase II study of carboplatin, pemetrexed, and bevacizumab in advanced nonsquamous non–small‐cell lung cancer
por: Laslett, Nicole F., et al.
Publicado: (2018)

nab-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis
por: Langer, Corey J., et al.
Publicado: (2021)

Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance
por: Grasse, Sabrina, et al.
Publicado: (2018)

Fibroblast Growth Factor Receptor 1 Amplification in Non-Small Cell Lung Cancer by Quantitative Real-Time PCR
por: Gadgeel, Shirish M., et al.
Publicado: (2013)

Phase II Clinical Trial of Genexol® (Paclitaxel) and Carboplatin for Patients with Advanced Non-small Cell Lung Cancer
por: Kim, Han Jo, et al.
Publicado: (2011)

Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer
por: Goto, Yasushi, et al.
Publicado: (2011)

Hypertension as a predictive biomarker in patients with advanced non-small-cell lung cancer treated with apatinib
por: Fang, Shen-Cun, et al.
Publicado: (2019)

Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy
por: Honrubia-Peris, Beatriz, et al.
Publicado: (2021)

Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer
por: Creelan, Ben C., et al.
Publicado: (2013)

Evaluation of calculating carboplatin dosage in carboplatin–pemetrexed therapy as the first‐line therapy for Chinese patients with advanced lung adenocarcinoma
por: Zhu, Yixiang, et al.
Publicado: (2018)

Depletion of HDAC6 Enhances Cisplatin-Induced DNA Damage and Apoptosis in Non-Small Cell Lung Cancer Cells
por: Wang, Lei, et al.
Publicado: (2012)

Randomized Phase II Study of Weekly Paclitaxel plus Carboplatin Versus Biweekly Paclitaxel plus Carboplatin for Patients with Previously Untreated Advanced Non‐Small Cell Lung Cancer
por: Takayama, Koichi, et al.
Publicado: (2019)

Clinical Significance of the Relationship between Progression-Free Survival or Postprogression Survival and Overall Survival in Patients with Extensive Disease-Small-Cell Lung Cancer Treated with Carboplatin plus Etoposide
por: Imai, Hisao, et al.
Publicado: (2016)

Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer
por: Boutsikou, Eftimia, et al.
Publicado: (2013)

Multi-Level Targeting of the Phosphatidylinositol-3-Kinase Pathway in Non-Small Cell Lung Cancer Cells
por: Zito, Christopher R., et al.
Publicado: (2012)

HDAC6 Regulates Radiosensitivity of Non-Small Cell Lung Cancer by Promoting Degradation of Chk1
por: Moses, Niko, et al.
Publicado: (2020)

Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung cancer
por: Minami, Seigo, et al.
Publicado: (2013)

Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib
por: Satouchi, M, et al.
Publicado: (2007)

Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy
por: Berardi, Rossana, et al.
Publicado: (2016)

Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non–small cell lung cancer
por: Okamoto, Isamu, et al.
Publicado: (2009)

Phase i study of 'dose-dense' pemetrexed plus carboplatin/radiotherapy for locally advanced non-small cell lung carcinoma
por: Shen, Xinglei, et al.
Publicado: (2011)

Comparative analysis of carboplatin and paclitaxel combination chemotherapy schedules in previously untreated patients with advanced non-small cell lung cancer
por: SHIMIZU, TOSHIKI, et al.
Publicado: (2013)

First‐line nab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: Results of the NEPTUN study
por: Dechow, Tobias, et al.
Publicado: (2021)

Phase I/II study of daily carboplatin, 5-fluorouracil and concurrent radiation therapy for locally advanced non-small-cell lung cancer
por: Yoshizawa, H, et al.
Publicado: (2003)

Implications of the USP10-HDAC6 axis in lung cancer - A path to precision medicine
por: Zhang, Xiaohong Mary, et al.
Publicado: (2016)

Advanced atypical lung carcinoid tumour successfully treated with carboplatin, etoposide and atezolizumab: A case report
por: Yamamoto, Yoshihiro, et al.
Publicado: (2022)

Correlation of Expression Levels of Copper Transporter 1 and Thymidylate Synthase with Treatment Outcomes in Patients with Advanced Non-small Cell Lung Cancer Treated with S-1/Carboplatin Doublet Chemotherapy
por: Konishi, Maho, et al.
Publicado: (2018)

Re-challenge chemotherapy with gemcitabine plus carboplatin in patients with non-small cell lung cancer
por: Khan, Khurum, et al.
Publicado: (2013)

Efficacy of paclitaxel‐carboplatin with bevacizumab as a late‐line therapy for patients with advanced nonsquamous non‐small cell lung cancer: A platinum rechallenge
por: Sugisaka, Jun, et al.
Publicado: (2023)

Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer
por: McKeage, M J, et al.
Publicado: (2008)

Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano.
por: Comella, P., et al.
Publicado: (1996)

Cannot write session to /tmp/vufind_sessions/sess_a5i7bv8ijd55fckchk27tkopk9